Literature DB >> 9252195

Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer.

N Harada1, S Gansauge, F Gansauge, H Gause, S Shimoyama, T Imaizumi, T Mattfeld, M H Schoenberg, H G Beger.   

Abstract

Recent studies have suggested a p53-independent expression of p21(WAF1/CIP1). We investigated the correlation between p53 overexpression and the expression of p21(WAF1/CIP1) in 57 patients with pancreatic adenocarcinoma. By means of reverse transcription and polymerase chain reaction (RT-PCR), we examined the mRNA levels of WAF1/CIP1 and compared them with the p53 status in 20 patients and in a further six pancreatic tumour cell lines. In pancreatic cancer tissues, immunohistological evaluation revealed a significant correlation between active p53 and p21(WAF1/CIP1) (P < 0.005) as well as WAF1/CIP1 mRNA expression (P < 0.005). This coherence was also evident in human pancreatic carcinoma cell lines. The analysis of p53 and p21(WAF1/CIP1) expression in relation to clinicopathological features revealed a significant correlation between p53 overexpression and tumour stage, tumour size, grading and lymph node metastases, whereas p21(WAF1/CIP1) expression correlated only with tumour size. We conclude that the expression of p21(WAF1/CIP1) normally depends on active p53, but that there may also exist p53-independent pathways of induction that reduce the correlation of p21(WAF1/CIP1) to clinicopathological features.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252195      PMCID: PMC2224055          DOI: 10.1038/bjc.1997.382

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

Review 2.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

3.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology.

Authors:  P A Hall; A Ray; N R Lemoine; C A Midgley; T Krausz; D P Lane
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

4.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

5.  The role of anti-p53-autoantibodies in pancreatic disorders.

Authors:  S Gansauge; F Gansauge; G Negri; P Galle; J Müller; A K Nüssler; B Poch; H G Beger
Journal:  Int J Pancreatol       Date:  1996-06

6.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

7.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.

Authors:  A L Børresen; E Hovig; B Smith-Sørensen; D Malkin; S Lystad; T I Andersen; J M Nesland; K J Isselbacher; S H Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

10.  Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

Authors:  C M Barton; S L Staddon; C M Hughes; P A Hall; C O'Sullivan; G Klöppel; B Theis; R C Russell; J Neoptolemos; R C Williamson
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  10 in total

1.  Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma.

Authors:  Y Ito; S Higashiyama; T Takeda; Y Yamamoto; K I Wakasa; N Matsuura
Journal:  Int J Pancreatol       Date:  2001

2.  Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).

Authors:  J Mitra; C Y Dai; K Somasundaram; W S El-Deiry; K Satyamoorthy; M Herlyn; G H Enders
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  Downregulation of p21/WAF1 is related to advanced and dedifferentiated laryngeal squamous cell carcinoma.

Authors:  P Hirvikoski; J K Kellokoski; E J Kumpulainen; J A Virtaniemi; R T Johansson; V M Kosma
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

Review 4.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

5.  Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.

Authors:  Sahar Nissim; Gregory E Idos; Bechien Wu
Journal:  Pancreas       Date:  2012-11       Impact factor: 3.327

Review 6.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

7.  p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.

Authors:  M A Anttila; V M Kosma; J Hongxiu; J Puolakka; M Juhola; S Saarikoski; K Syrjänen
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.

Authors:  J M Karjalainen; M J Eskelinen; J K Kellokoski; M Reinikainen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.

Authors:  G B Baretton; U Klenk; J Diebold; N Schmeller; U Löhrs
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.

Authors:  Matthew T Huggett; Slavica Tudzarova; Ian Proctor; Marco Loddo; Margaret G Keane; Kai Stoeber; Gareth H Williams; Stephen P Pereira
Journal:  Oncotarget       Date:  2016-04-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.